DLL4 and cancer: Notably, enoticumab, a fully human IgG1 monoclonal antibody that binds human Dll4, has been recently tested in human patients with advanced solid tumors, and demonstrated effective monotherapy clinical activity, as indicated by the observed prolonged stable disease in some of the cancers under study, and the partial response attained in patients with ovarian carcinoma and bronchioalveolar-type NSCLC [170].